Compare Incyte Corporation (INCY) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lemonade Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Lemonade Inc trades at $51.65 (market cap $4.09B). The key difference: Incyte Corporation is far larger — about 6× Lemonade Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| INCY | LMND | |
|---|---|---|
Market Cap | $24.54B | $4.09B |
Sector | Health | Financials |
52-Week High | $129.93 | $96.57 |
52-Week Low | $81.61 | $47.38 |
Enterprise Value | $20.04B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Lemonade (LMND) trades at $51.63, down 1.99% on the day, with a bearish technical signal from moving averages. Revenue growth is strong, reaching $737.9M in 2025, but the company remains unprofitable with a net income margin of -14.19%. Recent Q2 2026 earnings beat expectations, and the company targets positive adjusted EBITDA by Q4 2026, yet the stock faces selling pressure amid valuation concerns.
The outlook hinges on Lemonade's path to profitability; achieving its EBITDA target could drive upside toward the $58 consensus price target. Key risks include persistent losses, competitive pressures, and execution challenges in scaling its AI-driven insurance model. Investor sentiment is divided, reflecting the high-growth but high-burn profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
